Emergency Contraception Options: Focus on Ulipristal Acetate

被引:0
|
作者
Cameron, Sharon T. [1 ,2 ]
机构
[1] Chalmers Sexual & Reprod Hlth Serv, 2a Chalmers St, Edinburgh EH3 9ES, Midlothian, Scotland
[2] Univ Edinburgh, Royal Infirm Edinburgh, Dept Reprod & Dev Sci, Edinburgh EH16 5SU, Midlothian, Scotland
关键词
ulipristal acetate; progesterone receptor modulator; emergency contraception; levonorgestrel;
D O I
10.4137/CMWH.S7642
中图分类号
R71 [妇产科学];
学科分类号
100211 ;
摘要
Ulipristal acetate (UPA) is a progesterone receptor modulator that is available for emergency contraception (EC) and can be taken up to 120 hours after unprotected intercourse. A meta-analysis of clinical trials comparing UPA with levonorgestrel (LNG) for EC, demonstrated that UPA has higher efficacy than LNG. This higher efficacy is supported by biomedical studies that have demonstrated that UPA is a more potent inhibitor of ovulation, being able to delay ovulation in the immediate preovulatory period, when LNG is no longer effective. A recent study that explored risk factors for failure of EC, demonstrated that obese women were at increased risk of EC failure, with either UPA or LNG. However, failure was significantly less amongst women receiving UPA than those receiving LNG. There is growing evidence therefore, that UPA should be the preferred oral method of EC.
引用
收藏
页码:23 / 29
页数:7
相关论文
共 50 条
  • [21] Ulipristal Acetate: Review of the Efficacy and Safety of a Newly Approved Agent for Emergency Contraception
    Richardson, Ashley R.
    Maltz, Fraidy N.
    [J]. CLINICAL THERAPEUTICS, 2012, 34 (01) : 24 - 36
  • [22] Ulipristal Acetate: Critical Review About Endometrial and Ovulatory Effects in Emergency Contraception
    Mozzanega, Bruno
    Gizzo, Salvatore
    Di Gangi, Stefania
    Cosmi, Erich
    Nardelli, Giovanni Battista
    [J]. REPRODUCTIVE SCIENCES, 2014, 21 (06) : 678 - 685
  • [23] Use of ulipristal acetate and levonorgestrel for emergency contraception: a follow-up study
    Baird, Aisling Susan
    Trussell, James
    Webb, Anne
    [J]. JOURNAL OF FAMILY PLANNING AND REPRODUCTIVE HEALTH CARE, 2015, 41 (02): : 116 - 121
  • [24] Pregnancy outcome after failure of emergency contraception with ulipristal acetate - an observational study
    Hoeltzenbein, M.
    Wagner, J. K.
    Schaefer, C.
    Dathe, K.
    [J]. EUROPEAN JOURNAL OF HUMAN GENETICS, 2020, 28 (SUPPL 1) : 180 - 180
  • [25] Availability of ulipristal acetate: A secret shopper survey of pharmacies in a metropolitan area on emergency contraception
    French, Valerie A.
    Mattingly, Tateum L.
    Rangel, Ariana V.
    Shelton, Annie U.
    [J]. JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION, 2019, 59 (06) : 832 - 835
  • [26] Emergency contraception failure and ulipristal acetate exposure in pregnant women: First concerns and outcomes
    Ozturk, Z.
    [J]. NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2017, 390 : S75 - S76
  • [27] Ulipristal Acetate Taken 48-120 Hours After Intercourse for Emergency Contraception
    Fine, Paul
    Mathe, Henri
    Ginde, Savita
    Cullins, Vanessa
    Morfesis, Johanna
    Gainer, Erin
    [J]. OBSTETRICS AND GYNECOLOGY, 2010, 115 (02): : 257 - 263
  • [28] The rationale for use of Ulipristal Acetate as first line in emergency contraception: biological and clinical evidence
    Glasier, Anna
    [J]. GYNECOLOGICAL ENDOCRINOLOGY, 2014, 30 (10) : 688 - 690
  • [29] Pregnancy Outcomes Following Ulipristal Acetate Emergency Contraception Failure: A Report of Five Cases
    Ozturk, Zeynep
    Akgul, Emine
    [J]. FETAL AND PEDIATRIC PATHOLOGY, 2017, 36 (03) : 213 - 219
  • [30] Double dosing ulipristal acetate emergency contraception for individuals with obesity: a randomised crossover trial
    Edelman, Alison
    Hennebold, Jon D.
    Bond, Kise
    Lim, Jeong Y.
    Cherala, Ganesh
    Blue, Steven W.
    Kraft, Shawn P.
    Erikson, David W.
    Archer, David
    Jensen, Jeffery
    [J]. BMJ SEXUAL & REPRODUCTIVE HEALTH, 2024,